
    
      This is a single-dose, open-labeled, non-randomized, two-period study of Cysteamine
      Bitartrate Delayed-release Capsules (RP103) and CystagonÂ® in up to 10 patients (male or
      female) with nephropathic cystinosis under fasting conditions. It will involve a 4 night
      check-in to a clinical research center.
    
  